Iress scares investors with big CY22 profit downgrade
Nick Sundich, September 29, 2022
Iress (ASX:IRE) shares fell more than 15% this morning thanks to the company downgrading its profit guidance. The company said it was primarily a timing issue, with expected FY22 revenues being delayed until FY23. But it seems investors suspect there are other issues.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Iress downgrades its profit
Iress provides software to the financial services industry, including investment management and trading mechanisms. The company had forecast a full year Segment profit for FY22 (which for Iress is the calendar year) of $177m-$183m and an NPAT of $63m-$72m.
This morning it downgraded its Segment profit to $166-$170m and NPAT to $54m-$58m. The midpoints of the new guidance would be downgrades of 9% and 20% from the midpoints of the old guidance for Segment profit and NPAT respectively.
CEO Andrew Walsh asserted sales were still strong, but costs were higher than expected, including USD-priced technology and software. The timing delays meant some revenue would now be deferred into FY23.
Investors ignore the good news
The company’s shares dropped this morning even though there was some good news too.
IRESS (ASX:IRE) share price chart (Graph: TradingView)
Iress told investors it had been chosen by the Commonwealth Super Corporation (CSC), the provider of superannuation software to the public sector, to use IRESS software. The contract runs for an initial five years, but migration will be a more gradual process that will not be reflected in FY22. The first tranche of users will not have their migration completed until July next year.
This arguably explains why investors have seemingly ignored the good news.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Trump vs. Jerome Powell: What Happens to the Market If Powell Is Fired?
The relationship between President Donald Trump and Federal Reserve Chair Jerome Powell has often been tumultuous, particularly around decisions regarding…
Telix Pharmaceuticals (ASX:TLX): It’s made ~A$1.7bn in revenue from Illucix, but here’s why the best is yet to come!
What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful…
Anti Woke ETFs: Do they practice what they preach and have they outperformed since Trump’s return to power?
Have you ever heard of so-called ‘Anti Woke ETFs’? If you’re sick of companies that are big on ESG, this…